Alkermes (ALKS) Competitors $28.98 -0.02 (-0.07%) Closing price 08/26/2025 04:00 PM EasternExtended Trading$28.98 0.00 (0.00%) As of 08/26/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALKS vs. ABEO, MEDP, OMCL, AMN, INCY, UTHR, NBIX, BMRN, EXEL, and MDGLShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "medical" sector. Alkermes vs. Its Competitors Abeona Therapeutics Medpace Omnicell AMN Healthcare Services Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Alkermes (NASDAQ:ALKS) and Abeona Therapeutics (NASDAQ:ABEO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do analysts rate ALKS or ABEO? Alkermes currently has a consensus target price of $41.08, suggesting a potential upside of 41.76%. Abeona Therapeutics has a consensus target price of $19.50, suggesting a potential upside of 174.26%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ALKS or ABEO? In the previous week, Alkermes had 6 more articles in the media than Abeona Therapeutics. MarketBeat recorded 23 mentions for Alkermes and 17 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.57 beat Alkermes' score of 0.56 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility & risk, ALKS or ABEO? Alkermes has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Is ALKS or ABEO more profitable? Alkermes has a net margin of 23.15% compared to Abeona Therapeutics' net margin of 0.00%. Abeona Therapeutics' return on equity of 89.05% beat Alkermes' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% Abeona Therapeutics N/A 89.05%45.64% Do insiders & institutionals hold more shares of ALKS or ABEO? 95.2% of Alkermes shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 4.4% of Alkermes shares are held by insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better earnings and valuation, ALKS or ABEO? Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.51B3.18$367.07M$2.0813.93Abeona Therapeutics$3.50M104.17-$63.73M$0.7010.16 SummaryAlkermes beats Abeona Therapeutics on 9 of the 17 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.79B$3.07B$5.73B$9.74BDividend YieldN/A2.26%3.95%4.07%P/E Ratio13.9320.5230.3326.09Price / Sales3.18352.87423.38106.20Price / Cash10.9444.2437.7259.08Price / Book2.958.139.796.67Net Income$367.07M-$54.08M$3.27B$265.43M7 Day Performance0.03%4.48%3.65%3.36%1 Month Performance10.91%3.64%3.83%0.39%1 Year Performance2.80%7.34%32.34%19.43% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.6694 of 5 stars$28.98-0.1%$41.08+41.8%+1.6%$4.79B$1.51B13.931,800ABEOAbeona Therapeutics4.4118 of 5 stars$6.91-3.1%$19.50+182.2%+23.9%$354.35M$3.50M9.8790MEDPMedpace4.3067 of 5 stars$462.91+1.1%$406.60-12.2%+21.8%$13.00B$2.11B34.425,900Positive NewsOMCLOmnicell3.0091 of 5 stars$31.61-0.3%$46.71+47.8%-28.0%$1.45B$1.15B63.223,670News CoveragePositive NewsAMNAMN Healthcare Services4.5016 of 5 stars$19.43+2.7%$28.25+45.4%-61.5%$744.48M$2.98B-2.502,968Positive NewsINCYIncyte4.6601 of 5 stars$84.92-2.3%$81.20-4.4%+28.9%$16.58B$4.24B19.302,617UTHRUnited Therapeutics4.9251 of 5 stars$314.10+0.3%$382.00+21.6%-10.8%$14.17B$2.88B12.261,305Positive NewsAnalyst RevisionNBIXNeurocrine Biosciences4.8609 of 5 stars$133.14+0.2%$160.90+20.9%-10.1%$13.20B$2.36B39.391,800Positive NewsBMRNBioMarin Pharmaceutical4.9955 of 5 stars$57.44-0.2%$93.17+62.2%-36.2%$11.03B$2.85B17.043,040Positive NewsEXELExelixis4.8782 of 5 stars$37.76-1.4%$44.06+16.7%+49.0%$10.16B$2.17B18.151,147MDGLMadrigal Pharmaceuticals3.8569 of 5 stars$391.43+5.8%$439.71+12.3%+66.1%$8.69B$180.13M-30.4690Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Abeona Therapeutics Alternatives Medpace Alternatives Omnicell Alternatives AMN Healthcare Services Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALKS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in Am...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access